A novel system for stable, high-level expression from the T7 promoter
© Kesik-Brodacka et al.; licensee BioMed Central Ltd. 2012
Received: 6 June 2012
Accepted: 8 August 2012
Published: 16 August 2012
The most widespread, efficient prokaryotic protein-producing system is one where the T7 phage polymerase recognizes the T7 phage promoter (T7 p/p system). Unfortunately, in this system, target protein expression gradually declines and is often undetectable following 3 to 5 subcultures. Although a number of studies have attempted to stabilize the expression levels of the T7 p/p system, none has resolved the problem adequately and thus precludes the use of this system for the production of recombinant proteins on a large scale.
We created an expression cassette enabling stable, high-level expression in the T7p/p system. The cassette was tested with two different vector backbones and two target proteins. In all experiments, the expression system using the new cassette exhibited high and stable protein expression levels when compared to the traditional system.
Herein, we describe a universal expression cassette that enables high-level, stable target protein expression in T7 RNA polymerase-based expression systems. We also present the successful use of this cassette as a novel expression platform and demonstrate its ability to overcome the main deficiency of the T7 p/p system. Thus, we provide a method for using the T7 p/p system on an industrial scale.
KeywordsT7 expression Expression cassette Stable expression from T7 promoter High expression from T7 promoter
The potential to produce recombinant proteins in prokaryotic systems, which are difficult and/or expensive to enlist from natural sources, was a major breakthrough in biotechnology . It was enabled by a discovery in the 1980's, in which a system based on RNA polymerases, dependent upon DNA, was incorporated into host cells . These cells were transformed with vectors bearing a recombinant gene under the control of promoters recognized by these polymerases. Currently, one of the most widely used prokaryotic protein-producing systems uses the T7 phage polymerase that recognizes the T7 phage promoter . In many cases, this system has proven extremely effective and has permitted high levels of target protein expression to be obtained, up to 50% of the total cellular protein production . However, the system is not without its problems, especially a gradual decrease in the expression levels of the target gene. After several (3 to 5) subcultures, the induced expression levels may be comparable to basal expression levels, and often the host cells do not express detectable levels of the target protein . This results in a lower target protein yield. Previously, it was thought that decreased protein expression was caused by loss of, or mutations in, the plasmid bearing the target gene. Many attempts have been made to stabilize the expression levels of the T7 p/p system, including examination of plasmid stability by lowering the uninduced T7 polymerase production levels. Another approach used freshly transformed bacteria to obtain the target protein [5–9]. However, none of these approaches have resolved the problem adequately.
The aim of our study was to address the deficiencies of traditional T7 promoter-based systems and create a novel system enabling long-term, stable expression of target proteins in bacteria cell factories.
The basis for our strategy was that the major contributing factor of decreased expression levels in the T7-based system was random chromosomal mutations occurring in the sequence encoding the T7 phage RNA polymerase. Thus, selection pressure favored cells whose metabolism was not burdened by the production of the target protein . In traditional systems, non-overproducing cells quickly dominate the culture . Our approach aims to overcome the problem of reduced expression by eliminating non-overproducing cells from the culture. We achieved this goal by the creation of a stable expression T7C p/p system in which the loss of functional polymerase, T7 RNA polymerase promoter, plasmid and any failure disabling the production of the target recombinant protein induces the death of the host cell. Therefore, we maintain only target protein-expressing cells in the culture and achieve a stable high level of recombinant protein expression.
Results and discussions
The Type II selection marker was tightly linked to the expression of the target protein. This type of marker could be expressed only when all elements of the T7 phage promoter-based system remained functional. As a result, from the earliest culture stages, any damage that impaired a cell's ability to produce the target protein also caused it to stop producing the selection marker. Therefore, only those cells expressing the target protein were able to grow in the culture. The Type II selection marker is an integral part of the expression cassette.
To confirm that T7 polymerase is required and responsible for the expression of selection marker from the cassette we performed experiment A. In this experiment we transformed Bl21(DE3) and DH5α E. coli strains with plasmids containing the expression cassette. Bl21(DE3) is a λDE3 lysogen strain of E. coli, which harbors a genomic copy of the gene for T7 RNA polymerase under the control of the lac repressor. In this strain, T7 RNA polymerase is produced after induction with isopropyl-β-D-galactoside (IPTG).
Construction of the expression vectors
Expression vector name
Sequence encoding target protein
kE2 gene of CSFV virus.
PA-4D of B. anthracis
PA-4D of B. anthracis
kE2 gene of CSFV virus.
E. coli DH5α transformed with the plasmids were growing normally when plated on LB supplemented with Cm or Amp. However, bacteria of this strain did not grow on LB supplemented with Km. Type I selection marker independent from T7 polymerase is responsible for resistance to Cm and Amp antibiotics. On the other hand, resistance to Km is granted by Type II selection marker and is dependent on the presence of polymerase T7. As DH5α does not express the T7 polymerase, there is also no expression of Type II selection marker.
E. coli Bl21(DE3) transformed with appropriate plasmid grew on LB supplemented with Cm, Amp and Km. In our experiments it was observed, that even without induction with IPTG the basal expression level of T7 polymerase was sufficient to grant bacteria resistance to Km, as the cells grew in presence of Km without the IPTG induction.
The results from this experiment prove that the cassette exhibits the required characteristics: the bacteria are resistant to Km only when the T7 polymerase is produced.
Type of experiment
Antibiotic in selective medium
E. coli strain, BL21(DE3), was used for the overproduction of proteins in all the experiments.
Experiment C analyzed the difference in expression levels of the kE2 protein in E. coli harboring the p7KE2 expression vector between cultures with different selection markers: ampicillin resistance (AmpR) as the Type I marker and KmR as the Type II marker. Results of these experiments are shown in Figure 3C.
Experiment D compared the expression levels of the target polypeptide obtained in a commonly used system, T7 p/p, with the expression levels for the novel T7C p/p system described here. To this end, two vectors were used, a standard vector with the T7 phage promoter and an introduced sequence encoding PA-4D (pGPA), and a modified vector containing the sequence encoding PA-4D as a part of the expression cassette (pGKPA). We used two different selection markers: CmR as the Type I marker and KmR as the Type II marker. Results of these experiments are presented in Figure 3D.
Target protein expression levels were the same for both selection marker types between 4 to 6 hours after induction (Figure 3B,C,D). However, at 6 to 8 hours after protein expression induction, cultures with the Type I selection marker demonstrated diminished target protein expression levels. This phenomenon was observed in all three experiments (B, C and D). The gradual decrease in expression levels of the target gene is because of the Type I selection that forces the cell to retain the expression vector and protect the expression mechanism of the selection marker but not the target protein. Because overexpression of the target protein poses a significant burden on the host cell metabolism, cells that undergo mutations that allow the expression of the selection marker, but not the target protein, are favored, divide faster, and ultimately overgrow the culture.
In the experimental cultures with the Type II marker, we observed consistently high expression levels throughout the course of the experiments. Notably, the observed protein expression levels for this marker type were equal to initial protein expression levels observed in experiments using Type I marker. While the expression levels were stable for Type II marker, they were visibly declining for Type I marker.
Differences in expression levels between cultures with the Type I and Type II markers increased with time and were caused by the Type II marker allowing to survive only these cells which maintained the expression vector and had a correctly functioning expression system. This eliminated non-overproducer cells from the culture.
Our results show that improved stability did not impair the target protein expression levels. In addition the production level of the Type II selection factor is so low, that it is not seen on SDS-PAGE (Figure 3). Yet, as our experiments demonstrate, the expression level of the selection marker was sufficient to allow the host cells to grow and divide in the selection media. Additionally, our system exploited the phenomenon of the basal expression of T7 RNA polymerase, allowing medium containing the selective antibiotic to be used at all stages of the culture (even before induction). In traditional T7 p/p systems, the existence of even basal expression generates a burden on the host cells metabolism, giving a selective advantage to non-overproducing cells .
The T7C p/p system can also be used to express proteins toxic to E. coli cells. However, in this case basal expression is disadvantageous, and specialized commercially available strains expressing T7 lysozyme should be used . In addition, this case requires the selective antibiotic to be added to the medium after induction of T7 RNA polymerase production (data not shown).
The described T7C p/p system allows optimization of the target protein expression, indicating the possibility of obtaining high yields of the target protein in large-scale cultures. High target protein content at the time of culture harvest facilitates target protein purification.
An additional advantage of T7C system is the reduction of time-consuming laboratory procedures. Small-scale test expression is widely used as a predictive tool to determine which of the clones produces the target protein . Use of T7C system allows omission of this test by culturing of bacteria in the presence of an antibiotic from the earliest stage (even before induction). Therefore eliminating non-overproducing cells from the culture. The gain is especially notable when testing large numbers of genetic constructs for target protein expression.
In this study, we present a novel, universal method for stable, high-level recombinant protein production in bacterial cells. This method increases the efficiency and cost competitiveness of target protein production in bacterial cells. We demonstrate the applicability of this method for the enhancement of the T7 phage RNA polymerase-based expression system, the most widespread recombinant protein production system used in laboratories worldwide. We demonstrated the ability of this system to overcome the chief deficiency of the T7p/p system – the gradual decline of target protein production. We tested the method using two different vector backbones and two different target proteins. In all experiments, stable, high-level long-term expression of the target protein was attained.
This expression system can significantly enhance protein expression for both the laboratory and large-scale applications, and its use facilitates purification of recombinant proteins.
ECKm cassette construction
Primers used for cassettes and vector construction
Sequence (5′ → 3′)
Four synthetic oligonucleotides (Tryp1, Tryp2, Tryp3, and Tryp4) were ligated to form a synthetic DNA fragment encoding the transcription terminator sequence of the tryptophan operon. A TAA translational stop codon (designated S), Sal I "sticky" end and Not I restriction site were added to the 5’-end of the fragment. A Not I "sticky" end was introduced at the 3’-end of the fragment. The created DNA fragment was designated S + TT.
The DNA fragment containing the region encoding aminoglycoside-3’-phosphotransferase (APH) (kanamycin resistance gene) and 10 nt of non-coding sequence upstream of the gene was amplified by PCR with Sal INot I 5'Kan and Hin dIII 3'Kan primers. Sal I and Not I restriction sites were added to the 5’-end. A Hin dIII restriction site and a TAA translation termination codon were introduced at the 3’-end of the amplified fragment. The PCR fragment was digested with Sal I and Hin dIII.
The digested S + TT DNA fragment and the APH gene fragment were ligated together to create the ECKm cassette.
Expression vector construction
To clone the expression cassettes, we used two plasmid backbones: pIGDMCT7RS and pT7RS [GenBank accession nos. DQ485721 and AY923866, respectively]. These vectors carry a T7 phage RNA polymerase promoter, a sequence encoding the translational stop codon of the T7 phage and genes encoding AGA and AGG tRNAs, which supplement the shortage of these tRNAs that results from the codon usage in E. coli. Both plasmids carry resistance genes, allowing the selection of bacteria harboring these plasmids. pIGDMCT7RS carries a chloramphenicol resistance gene, CatA1, and pT7RS carries an ampicillin resistance gene.
The ECKm cassette was cloned into the pIGDMCT7RS and pT7RS backbones between the Sal I and Hin dIII restriction sites, and the resulting plasmids were designated pGK and p7K, respectively.
For target proteins, two different polypeptides originating from two organisms were used: a 220 amino acid (aa) fragment of the E2 (kE2) protein from Classical Swine Fever Virus (CSFV) and PA-4D (143 aa) of Bacillus anthracis.
The complete nucleotide sequence of the E2 antigen of CSFV was used to amplify kE2, a 1023 bp fragment corresponding to nt 2428–3087, according to the E2 sequence [GenBank accession no. M31768]. The sequence was amplified by PCR with Nde I 5'E2 and Xho I 3'E2 primers. An Nde I site and GCA codon were added, and the guanine was altered to a thymine at the 5’-end. A Hin dIII restriction site and TAA translation stop codon were introduced at the 3’-end of the amplified fragment. The kE2 fragment was digested with Nde I and Hin dIII restriction enzymes and cloned into pGK using the same restriction sites. The resulting vector was designated pGKE2 (Figure 2A).
To create p7KE2 (Figure 2B), a segment consisting of the sequences encoding kE2, the transcription terminator sequence from the tryptophan operon, and APH was removed from the pGKE2 vector using Nde I and Hin dIII restriction enzymes and shuttled into the pT7RS backbone at the Nde I-Hin dIII restriction sites.
The complete nucleotide sequence of the protection antigen (PA) of Bacillus anthracis was used to amplify the fourth domain (PA-4D) of PA, a 429 bp fragment, according to the PA sequence [GenBank accession no. AF065404]. Two amplifications were conducted: the first one with Nde I 5'PA4D and Sal I 3'PA4D primers; the second with Nde I 5'PA4D and Hin dIII 3'PA4D primers. Because of the first amplification, an Nde I restriction site was added at the 5’-end, and a Sal I restriction site was added at the 3’-end of the amplified fragment. In the second amplification, an Nde I restriction site was added at the 5’-end, and a Hin dIII restriction site was added at the 3’-end of the amplified fragment. The amplified fragment was then digested with Nde I and Sal I and cloned into the pGK vector at the corresponding restriction sites. The final vector was designated pGKPA (Figure 2C). The fragment digested with Nde I and Hin dIII was cloned into the Nde I/Hin dIII restriction sites of pIGDMCT7RS. The final vector was designated pGPA (Figure 2D).
All described vectors are summarized in Table 1.
Expression of selection markers
In the experiments were used competent DH5α and Bl21(DE3) E. coli strains purchased form Stratagene. Bacteria were transformed with plasmids pGKPA, pGKE2, p7KE2. All these plasmids contain ECKm expression cassette. After the transformation bacteria were plated in duplicate onto LB medium supplemented with appropriate antibiotic: ampicillin-(100 mg/l), chloramphenicol-(18 mg/l), kanamycin-(25 mg/l).
Expression of the target protein using expression vectors with the ECKm cassette
The Escherichia coli BL21(DE3) strain was used for overproduction of recombinant proteins in all experiments. The bacteria strain was obtained from Stratagene. E. coli bacteria harboring the appropriate recombinant plasmid were grown in 3 ml of Luria Bertani medium (10 g/L tryptone, 10 g/L NaCl, and 5g/L yeast extract) at 37°C for 3 hours. The cultures were then diluted with fresh medium (1:100) and shaken at 37°C until the A600 reached 0.4–0.7. Subsequently, the target polypeptide expression was induced by the addition of IPTG (0.1 mM final concentration), and the shaking was continued for 12 to 20 hours. Media used in the experiments contained the appropriate antibiotic: kanamycin (25 mg/l), chloramphenicol (18 mg/l), or ampicillin (100 mg/l).
Samples for A600 measurements and electrophoretic separation on polyacrylamide gels (SDS-PAGE) were collected every 2 hours after induction.
The presence and quantity of the target polypeptide was determined by separation of the bacterial lysate on a 15% polyacrylamide gel (SDS-PAGE), carried out as described by Laemmli . The separated proteins were visualized by staining with Coomassie Brilliant Blue G.
Polymerase chain reaction
Sodium dodecyl sulphate.
Funding for the project derives from the European Community funds of the European Fund for Regional Development POIG.01.01.02-00-007/08-00.
- Swartz JR: Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol. 2001, 12: 195-201. 10.1016/S0958-1669(00)00199-3View Article
- Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW: Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990, 185: 60-89.View Article
- Gräslund S, et al: Protein production and purification. Nat Methods. 2008, 5: 135-146. 10.1038/nmeth.f.202View Article
- Jevsevar S, Gaberc-Porekar V, Fonda I, Podobnik B, Grdadolnik J, Menart V: Production of nonclassical inclusion bodies from which correctly folded protein can be extracted. Biotechnol Prog. 2005, 21: 632-639.View Article
- Vethanayagam JG, Flower AM: Decreased gene expression from T7 promoters may be due to impaired production of active T7 RNA polymerase. Microb Cell Fact. 2005, 4: 3- 10.1186/1475-2859-4-3View Article
- Saïda F, Uzan M, Odaert B, Bontems F: Expression of highly toxic genes in E. coli: special strategies and genetic tools. Curr Protein Pept Sci. 2006, 7: 47-56. 10.2174/138920306775474095View Article
- Studier FW: Use of bacteriophageT7 lysozyme to improve an inducible T7expression system. J Mol Biol. 1991, 219: 37-44. 10.1016/0022-2836(91)90855-ZView Article
- Jana S, Deb JK: Strategies for efficient production of heterologous proteins in Escherichia coli. Appl Microbiol Biotechnol. 2005, 67: 289-298. 10.1007/s00253-004-1814-0View Article
- Mertens N, Remaut E, Fiers W: Tight transcriptional control mechanism ensures stable high-level expression from T7 Promoter-based expression plasmids. Nat Biotechnol. 1995, 13: 175-179. 10.1038/nbt0295-175.View Article
- Tyo KE, Ajikumar PK, Stephanopoulos G: Stabilized gene duplication enables long-term selection-free heterologous pathway expression. Nat Biotechnol. 2009, 27: 760-765. 10.1038/nbt.1555View Article
- Kelley KC, Huestis KJ, Austen DA, Sanderson CT, Donoghue MA, Stickel SK, Kawasaki ES, Osburne MS: Regulation of sCD4-183 gene expression from phage-T7-based vectors in Escherichia coli. Gene. 1995, 156: 33-36. 10.1016/0378-1119(95)00008-TView Article
- Sambrook J, Russell DW: Molecular Cloning A Laboratory Manual. 2001, Cold Spring Harbor New York: Cold Spring Harbor Laboratory Press,
- Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: Current Protocols in Molecular Biology. 1994, Brooklyn, New York: John Wiley and Sons, Inc
- Laemmli UK: Cleavage of structurals proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.